Evidence map›Paper›PMID 40502874›Full record

ArticleCureus2025

Exploratory Analysis of Serum Oxidized Albumin as a Potential Prognostic Indicator for Diabetic Microvascular Complications: A Retrospective Cohort Pilot Study.

Tomoya Kawaguchi, Yuka Kobayashi, Keiko Yasukawa, Kengo Miyoshi, Nagisa Ishibashi, Satoshi Usami, Yosuke Inaba, Masaya Sato, Makoto Kurano, Ryo Suzuki and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tomoya KawaguchiDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.
Yuka KobayashiDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.
Keiko YasukawaDepartment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, JPN.
Kengo MiyoshiDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.
Nagisa IshibashiDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.
Satoshi UsamiGraduate School of Education, The University of Tokyo, Tokyo, JPN.
Yosuke InabaSchool of Medicine, Chiba University, Chiba, JPN.
Masaya SatoDepartment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, JPN.
Makoto KuranoDepartment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, JPN.
Ryo SuzukiDepartment of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo, JPN.
Tomohisa AoyamaDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.
Yutaka YatomiDepartment of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, JPN.
Toshimasa YamauchiDepartment of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Oxidative stress is known to play a key role in the pathogenesis of diabetic complications. However, a useful biomarker of oxidative stress has not yet been widely adopted in clinical practice. We explored whether the ratio of serum oxidized albumin (human non-mercaptalbumin, HNA) to total albumin (HNA%) is associated with the five-year prognosis of diabetic complications. Methods In this single-center, retrospective cohort pilot study, we evaluated participants with diabetes who had been hospitalized at baseline and regularly followed up as outpatients. We measured the HNA% at baseline and at a five-year follow-up and assessed the development or progression of diabetic complications. We examined the relationship between baseline HNA% and changes in diabetic complications. Results In participants with simple diabetic retinopathy at baseline, lower baseline HNA% was associated with shorter duration of diabetes and with five-year improvement of retinopathy, irrespective of follow-up glycated hemoglobin levels (25.46% vs. 33.71%, p = 0.021). Additionally, in the overall cohort and in the subgroup with baseline chronic kidney disease (CKD) stage G2, baseline HNA% above the cutoff value was associated with increased risk of CKD progression (overall: RR 1.61, p = 0.042, stage G2 only: RR 1.83, p = 0.047). Regarding macrovascular complications, follow-up HNA%, but not baseline HNA%, was related to their development. Conclusions These exploratory findings suggest that HNA% may have potential as an indicator of the five-year prognosis of diabetic retinopathy and diabetic kidney disease. Further prospective studies are warranted to validate these findings.

Indexed as

biomarkerdiabetic complicationshuman mercaptalbuminoxidative stresspilot study

Identifiers

PMID40502874
PMCPMC12158403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.